Advantages and disadvantages of using Carbon Nanostructures in Reproductive Medicine: two sides of the same coin
Carbon nanostructures offer potential applications in reproductive medicine, but also pose reproductive system toxicity risks due to reactive oxygen species and oxidative stress.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This paper reviews the use of carbon nanostructures of many shapes (e.g., graphene derivatives and single- or multi-walled carbon nanotubes, fullerene, lipid nanostructures) in reproductive medicine, describing high-level applications such as improving sperm fertility and culture outcomes, enabling ART delivery systems for hormones, gamete/embryo selection, gene transfer and labeling, and roles in reproductive oncology diagnostics/therapy and infection prevention. It highlights both potential benefits and an explicit limitation of the literature balance, stating that risks and toxicity—especially reproductive-system toxicity—have received much less attention than positive mechanisms. Across reviewed studies, adverse effects have been reported for many nanostructure types, with SWCNTs described as having the highest side effects and fullerene the lowest, while functionalized graphene (e.g., –COOH, –NH2) is reported to increase toxicity; proposed mechanisms include reactive oxygen species/oxidative stress, disruption of sexual hormones and Leydig cells, reduced sperm motility/viability, and altered ovarian gene/cytokine pathways or steroidogenesis. It also notes that male reproductive toxicity appears greater than female toxicity, attributed to fewer protective mechanisms for the testes. Relevance to endometriosis: the review mentions carbon nanostructures as an alternative to surgical intervention in ectopic pregnancy and explicitly includes “endometriosis” among the reproductive conditions discussed for potential use of these nanostructures.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
5,521 characters
· extracted from
pmc-nxml
· 1 sections
· click to expand
Background
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-07T06:07:27.085738+00:00
- pubmed
- last seen: 2026-05-13T22:24:14.728497+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
Courtesy of the U.S. National Library of Medicine